Cite
MLA Citation
Dean A Fennell et al.. “Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.” Lancet, vol. 9, no. 6, 2021, pp. 593–600. http://access.bl.uk/ark:/81055/vdc_100131047947.0x000021